Explore
Validate
Learn
Western blot
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB814-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human IFN-beta Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from ascites. Detects human IFN-beta in Western blots. In Western blots, this antibody does not cross-react with recombinant human IFN-alpha .
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
P01574- Isotype
- IgG
- Antibody clone number
- 76703
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references PUM1 is a biphasic negative regulator of innate immunity genes by suppressing LGP2.
Sialylation of Campylobacter jejuni endotoxin promotes dendritic cell-mediated B cell responses through CD14-dependent production of IFN-β and TNF-α.
An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products.
Liu Y, Qu L, Liu Y, Roizman B, Zhou GG
Proceedings of the National Academy of Sciences of the United States of America 2017 Aug 15;114(33):E6902-E6911
Proceedings of the National Academy of Sciences of the United States of America 2017 Aug 15;114(33):E6902-E6911
Sialylation of Campylobacter jejuni endotoxin promotes dendritic cell-mediated B cell responses through CD14-dependent production of IFN-β and TNF-α.
Huizinga R, van Rijs W, Bajramovic JJ, Kuijf ML, Laman JD, Samsom JN, Jacobs BC
Journal of immunology (Baltimore, Md. : 1950) 2013 Dec 1;191(11):5636-45
Journal of immunology (Baltimore, Md. : 1950) 2013 Dec 1;191(11):5636-45
An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products.
Meager A, Dolman C, Dilger P, Bird C, Giovannoni G, Schellekens H, Thorpe R, Wadhwa M
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2011 Apr;31(4):383-92
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2011 Apr;31(4):383-92
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- IFN-beta Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN-beta Antibody. Recombinant Human IFN-beta (Catalog # 8499-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IFN-beta (50 pg/mL) is neutralized (green line) by increasing concentrations of Human IFN-beta Monoclonal Antibody (Catalog # MAB814). The ND50 is typically 7-21 µg/mL.
